-
29 August 2025 23:05:32
- Source: Sharecast
29 August 2025
Convatec Group Plc
("Convatec" or "the Company")
Director/PDMR Shareholding
Purchase of Ordinary Shares
The Company has been notified of the following transactions in relation to Persons Discharging Managerial Responsibility ("PDMR") in respect of ordinary shares of 10 pence each in the Company ("Shares").
On 28 August 2025, Jonny Mason, Interim Chief Executive Officer, purchased 50,000 Shares at an average price of 234.81 pence per Share.
On the same day, Fiona Ryder, Interim Chief Financial Officer purchased 21,263 Shares at an average price of 233.96 pence per Share.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name
|
Jonny Mason |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Interim Chief Executive Officer and PDMR |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name
|
Convatec Group Plc |
||||
|
b)
|
LEI
|
213800LS272L4FIDOH92 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary share of 10p each in Convatec Group Plc |
||||
|
|
|
|||||
|
Identification code |
GB00BD3VFW73 |
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction |
Purchase of Ordinary Shares |
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information |
|
||||
|
|
|
|||||
|
- Aggregated volume |
N/A - single transaction |
|||||
|
|
|
|||||
|
- Price |
|
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
28 August 2025 |
||||
|
f)
|
Place of the transaction
|
London Stock Exchange |
||||
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
Name
|
Fiona Ryder |
||||
|
Reason for the notification
|
|||||
|
Position/status
|
Interim Chief Financial Officer and PDMR |
||||
|
Initial notification /Amendment
|
Initial notification |
||||
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
Name
|
Convatec Group Plc |
||||
|
LEI
|
213800LS272L4FIDOH92 |
||||
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
Description of the financial instrument, type of instrument |
Ordinary share of 10p each in Convatec Group Plc |
||||
|
|
|
||||
|
Identification code |
GB00BD3VFW73 |
||||
|
|
|
||||
|
Nature of the transaction |
Purchase of Ordinary Shares |
||||
|
Price(s) and volume(s)
|
|
||||
|
Aggregated information |
|
||||
|
|
|
||||
|
- Aggregated volume |
N/A - single transaction |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
Date of the transaction
|
28 August 2025 |
||||
|
Place of the transaction
|
London Stock Exchange |
||||
Contacts
The person responsible for making this announcement is James Kerton, Company Secretary, Convatec Group plc: cosec@convatec.com
Media: MediaRelations@convatec.com
Investor Relations: IR@convatec.com
Convatec Group Plc's LEI code is 213800LS272L4FIDOH92
Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.